SNX3 exacerbates hepatic fibrosis by amplifying TGF-β1/Smad signaling pathway in hepatocyte-HSC fibrotic loop

IF 14.6 1区 医学 Q1 PHARMACOLOGY & PHARMACY
Acta Pharmaceutica Sinica. B Pub Date : 2026-09-01 Epub Date: 2026-06-15 DOI:10.1016/j.apsb.2026.06.021
Jing Zhang, Yuxing Dai, Jiaying Yu, Yilin Chen, Dinghu Ma, Wenjing Yu, Mingxia Peng, Zeyu Li, Jing Lu, Honghai Xu, Suowen Xu, Duanping Sun, Peiqing Liu
{"title":"SNX3 exacerbates hepatic fibrosis by amplifying TGF-β1/Smad signaling pathway in hepatocyte-HSC fibrotic loop","authors":"Jing Zhang,&nbsp;Yuxing Dai,&nbsp;Jiaying Yu,&nbsp;Yilin Chen,&nbsp;Dinghu Ma,&nbsp;Wenjing Yu,&nbsp;Mingxia Peng,&nbsp;Zeyu Li,&nbsp;Jing Lu,&nbsp;Honghai Xu,&nbsp;Suowen Xu,&nbsp;Duanping Sun,&nbsp;Peiqing Liu","doi":"10.1016/j.apsb.2026.06.021","DOIUrl":null,"url":null,"abstract":"<div><div>Hepatic fibrosis is a chronic disease driven by dysregulated TGF-<em>β</em>1-mediated interactions between hepatocytes and hepatic stellate cells. The molecular mechanisms controlling TGF-<em>β</em>1 degradation <em>versus</em> secretion remain poorly understood. Here, we identify sorting nexin 3 (SNX3), a retromer-associated cargo-binding protein, as a critical regulator of TGF-<em>β</em>1-driven hepatic fibrosis. SNX3 expression was significantly elevated in liver tissues from fibrosis patients and mouse models, correlating positively with TGF-<em>β</em>1 signaling. Functional studies using conditional mouse models demonstrated that hepatocyte-specific SNX3 knockout provided substantial protection against fibrosis, while overexpression induced spontaneous liver fibrosis. Mechanistically, SNX3 binds TGF-<em>β</em>1 and prevents its lysosomal degradation by promoting retention in early endosomes, thereby enhancing secretion. In hepatocytes, SNX3 increases TGF-<em>β</em>1 secretion that activates neighboring hepatic stellate cells through paracrine signaling. In activated hepatic stellate cells, elevated SNX3 expression further amplifies TGF-<em>β</em>1 production, creating a self-perpetuating fibrotic cascade leading to enhanced downstream signaling and transcriptional activation of fibrotic genes. Pharmacological studies validated therapeutic potential, with TGF-<em>β</em>1 signaling inhibition attenuating SNX3-induced fibrosis while pathway activation abolished SNX3 knockout protection, establishing SNX3 as a promising therapeutic target.</div></div>","PeriodicalId":6906,"journal":{"name":"Acta Pharmaceutica Sinica. B","volume":"16 9","pages":"Pages 6013-6029"},"PeriodicalIF":14.6000,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta Pharmaceutica Sinica. B","FirstCategoryId":"92","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2211383526003667","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/6/15 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Hepatic fibrosis is a chronic disease driven by dysregulated TGF-β1-mediated interactions between hepatocytes and hepatic stellate cells. The molecular mechanisms controlling TGF-β1 degradation versus secretion remain poorly understood. Here, we identify sorting nexin 3 (SNX3), a retromer-associated cargo-binding protein, as a critical regulator of TGF-β1-driven hepatic fibrosis. SNX3 expression was significantly elevated in liver tissues from fibrosis patients and mouse models, correlating positively with TGF-β1 signaling. Functional studies using conditional mouse models demonstrated that hepatocyte-specific SNX3 knockout provided substantial protection against fibrosis, while overexpression induced spontaneous liver fibrosis. Mechanistically, SNX3 binds TGF-β1 and prevents its lysosomal degradation by promoting retention in early endosomes, thereby enhancing secretion. In hepatocytes, SNX3 increases TGF-β1 secretion that activates neighboring hepatic stellate cells through paracrine signaling. In activated hepatic stellate cells, elevated SNX3 expression further amplifies TGF-β1 production, creating a self-perpetuating fibrotic cascade leading to enhanced downstream signaling and transcriptional activation of fibrotic genes. Pharmacological studies validated therapeutic potential, with TGF-β1 signaling inhibition attenuating SNX3-induced fibrosis while pathway activation abolished SNX3 knockout protection, establishing SNX3 as a promising therapeutic target.
SNX3通过放大肝细胞- hsc纤维化环中TGF-β1/Smad信号通路加重肝纤维化
肝纤维化是一种由TGF-β1介导的肝细胞与肝星状细胞相互作用失调驱动的慢性疾病。调控TGF-β1降解与分泌的分子机制尚不清楚。在这里,我们确定了分类连接蛋白3 (SNX3),一种逆转录物相关的货物结合蛋白,作为TGF-β1驱动的肝纤维化的关键调节因子。SNX3在纤维化患者和小鼠模型肝组织中表达显著升高,与TGF-β1信号通路呈正相关。使用条件小鼠模型的功能研究表明,肝细胞特异性SNX3敲除对纤维化具有实质性保护作用,而过表达则诱导自发性肝纤维化。机制上,SNX3结合TGF-β1,通过促进早期内体的滞留,阻止其溶酶体降解,从而促进分泌。在肝细胞中,SNX3增加TGF-β1分泌,TGF-β1通过旁分泌信号激活邻近的肝星状细胞。在活化的肝星状细胞中,SNX3表达的升高进一步放大了TGF-β1的产生,形成了一个自我延续的纤维化级联,导致下游信号传导和纤维化基因的转录激活增强。药理研究证实了其治疗潜力,TGF-β1信号抑制可减轻SNX3诱导的纤维化,而通路激活可消除SNX3敲除保护,使SNX3成为一个有希望的治疗靶点。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Acta Pharmaceutica Sinica. B
Acta Pharmaceutica Sinica. B Pharmacology, Toxicology and Pharmaceutics-General Pharmacology, Toxicology and Pharmaceutics
CiteScore
22.40
自引率
5.50%
发文量
1051
审稿时长
19 weeks
期刊介绍: The Journal of the Institute of Materia Medica, Chinese Academy of Medical Sciences, and the Chinese Pharmaceutical Association oversees the peer review process for Acta Pharmaceutica Sinica. B (APSB). Published monthly in English, APSB is dedicated to disseminating significant original research articles, rapid communications, and high-quality reviews that highlight recent advances across various pharmaceutical sciences domains. These encompass pharmacology, pharmaceutics, medicinal chemistry, natural products, pharmacognosy, pharmaceutical analysis, and pharmacokinetics. A part of the Acta Pharmaceutica Sinica series, established in 1953 and indexed in prominent databases like Chemical Abstracts, Index Medicus, SciFinder Scholar, Biological Abstracts, International Pharmaceutical Abstracts, Cambridge Scientific Abstracts, and Current Bibliography on Science and Technology, APSB is sponsored by the Institute of Materia Medica, Chinese Academy of Medical Sciences, and the Chinese Pharmaceutical Association. Its production and hosting are facilitated by Elsevier B.V. This collaborative effort ensures APSB's commitment to delivering valuable contributions to the pharmaceutical sciences community.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书